Nexvet Biopharma plc Ordinary Shares
NVET
NVET was delisted on the 28th of July, 2017.
17 hedge funds and large institutions have $23.8M invested in Nexvet Biopharma plc Ordinary Shares in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 0 closing their positions.
13% more funds holding
Funds holding: 15 → 17 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less capital invested
Capital invested by funds: $26.7M → $23.8M (-$2.88M)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LLC
Latimer Light Capital
New York
|
+$321K |
| 2 |
BC
Broadfin Capital
New York
|
+$81.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$14.7K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.26K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$379K |
| 2 |
CI
Cowen Inc
New York
|
-$60.9K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$10.4K |
| 4 |
Morgan Stanley
New York
|
-$3.6K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$389 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FCM
1
Farallon Capital Management
San Francisco,
California
| $11M | – | – | – |
|
|
BC
2
Broadfin Capital
New York
| $4.22M | +$81.8K | +17,255 | +2% |
|
|
FCMI
3
Foresite Capital Management II
Larkspur,
California
| $3.74M | – | – | – |
|
|
4
Adage Capital Partners
Boston,
Massachusetts
| $3.3M | -$379K | -80,000 | -9% |
|
|
BC
5
Boxer Capital
San Diego,
California
| $643K | – | – | – |
|
|
LLC
6
Latimer Light Capital
New York
| $436K | +$321K | +67,647 | +181% |
|
|
BCM
7
Bridgeway Capital Management
Houston,
Texas
| $185K | – | – | – |
|
8
Norges Bank
Oslo,
Norway
| $140K | – | – | – |
|
|
CI
9
Cowen Inc
New York
| $61K | -$60.9K | -12,843 | -47% |
|
|
10
Bank of America
Charlotte,
North Carolina
| $41K | -$10.4K | -2,190 | -18% |
|
11
Citigroup
New York
| $24K | – | – | – |
|
|
12
Morgan Stanley
New York
| $14K | -$3.6K | -760 | -19% |
|
|
13
UBS Group
Zurich,
Switzerland
| $13K | +$14.7K | +3,096 | New |
|
|
14
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $4K | -$389 | -82 | -6% |
|
|
TRCT
15
Tower Research Capital (TRC)
New York
| $3K | +$3.26K | +687 | New |
|
16
Acadian Asset Management
Boston,
Massachusetts
| $2K | – | – | – |
|
NVET Hedge Fund Activity: Q3 2016 in Review
17 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Nexvet Biopharma plc Ordinary Shares (NVET) for Q3 2016, worth a combined $23.8M — down 11% from $26.7M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new NVET positions and 0 closed out — a net gain of 2 holders — while 2 added to existing stakes and 5 trimmed.
The largest buyer was Latimer Light Capital, adding an estimated $321K. The largest seller was Adage Capital Partners, cutting an estimated $379K.
- 17 institutional investors held Nexvet Biopharma plc Ordinary Shares (NVET) as of Q3 2016, up from 15 in Q2 2016.
- Funds reported $23.8M of Nexvet Biopharma plc Ordinary Shares stock for Q3 2016, down 11% quarter-over-quarter.
- 2 funds opened new Nexvet Biopharma plc Ordinary Shares positions in Q3 2016 and 0 closed out, a net change of +2 holders.
- The largest Nexvet Biopharma plc Ordinary Shares buyer in Q3 2016 was Latimer Light Capital, an estimated $321K added.
- The largest Nexvet Biopharma plc Ordinary Shares seller in Q3 2016 was Adage Capital Partners, an estimated $379K sold.
Based on aggregated 13F filings for Q3 2016.